Islet Transplantation Using Campath-1H and Infliximab Induction
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Islet transplantation has been investigated as a treatment for Type 1 diabetes mellitus in
selected patients with inadequate glucose control despite insulin therapy. However, the
perennial hope that such an approach would result in long-term freedom from the need for
exogenous insulin, with stabilization of the secondary complications of diabetes, has failed
to materialize in practice. The goal of the present study is therefore to improve the safety
and efficacy of clinical islet-alone transplantation by minimizing dependence on
calcineurin-inhibitor therapy - thereby avoiding potential nephrotoxicity, and furthermore
improving success with single-donor islet infusions by avoiding all diabetogenic
immunosuppression. Campath-1H, combined with Infliximab induction therapy provides a unique
opportunity to minimize dosing of maintenance long-term immunosuppression while further
promoting islet engraftment.